TIDMIMM
RNS Number : 0424H
Immupharma PLC
30 July 2021
30 July 2021
ImmuPharma PLC
("ImmuPharma" or the "Company")
BOARD CHANGES
ImmuPharma PLC (LSE:IMM; Euronext Growth Brussels: ALIMM), the
specialist drug discovery and development company, provides
notification of changes to its Board of Directors.
Over the last year, ImmuPharma has continued to progress
Lupuzor(TM) toward its international Phase 3 trial in conjunction
with its partner, Avion Pharmaceuticals. In addition, the Company
has been active in repositioning and further developing its key
assets in the earlier stage development portfolio, including
programmes being run in its wholly-owned subsidiary Ureka Pharma
SAS.
At this time, Dimitri Dimitriou, Chief Executive Officer
('CEO'), has informed the Board that he wishes to step down from
his position, in order to pursue a number of other external
opportunities.
The Board would like to express its gratitude to Dimitri for his
16 years of service and wishes him well for the future.
Tim McCarthy, Chairman, has been appointed as CEO. The Company
has initiated a process to identify a suitable person to take over
as Non-Executive Chair of the Company and during this interim
period Tim will continue as Chairman.
Further, Dr Franco di Muzio, Senior Non-Executive Director
('NED') and Dr Stéphane Méry, ('NED'), have also decided that now
is an appropriate time for each of them to step down from the Board
following 14 and 6 years in these roles respectively.
The Board would like to express its gratitude to Franco and
Stéphane and wish them both well for the future.
As a consequence of Franco and Stéphane stepping down, the
Company has recognised the need to identify new NEDs to take the
Company through its next stage of development, with direct
experience in building a more diverse drug development business
together with current public market experience.
We are therefore pleased to announce today the appointment of Dr
Sanjeev Pandya as Senior independent NED. Sanjeev has over 25 years
of healthcare and international management experience. Sanjeev was
formerly CEO of Advanced Oncotherapy Plc, a specialist cancer
radiotherapy business listed on AIM. During his leadership, Sanjeev
raised over $100m and developed and secured partnerships in the
USA, EU, China, Singapore, India, Australia, Asia and South
America. Formerly, Sanjeev had a number of leadership roles in
several global clinical trials at Pfizer and was head of Europe
Regulatory and Medical at Reckitt Benckiser. The experience Sanjeev
brings in growing drug development businesses and mentoring
commercial and clinical teams, will be hugely invaluable to
ImmuPharma, as we move through our next phase of development.
In addition, Lisa Baderoon has been appointed to the Board as a
NED. Lisa has been advising ImmuPharma since its flotation on AIM
in 2006 and was appointed Head of Investor Relations in 2012.
Lisa's key activities over the last period have been in providing
strategic advice to the Board and liaising with investors,
stakeholders and advisors of the Company. On joining the Board Lisa
will be ensuring that shareholders' views and interests continue to
be fully represented. Formerly, Lisa was a longstanding Partner at
London based Buchanan Communications, one of the leading Financial
PR agencies and part of WPP plc, heading up the Healthcare
division. Lisa is also the founder of Just B Communications Ltd, a
bespoke advisory consultancy to both private and public
companies.
The Company has initiated a process to identify one other
additional new NED with the relevant skills and experience, who
will join the Board in due course.
All Board changes take place with immediate effect.
Commenting on the Board changes, Tim McCarthy, Chief Executive
Officer said: "We would like to take this opportunity to thank
Dimitri, Franco and Stéphane for their hard work during their time
in the business. In particular, having co-founded ImmuPharma in
2005, Dimitri has put in a considerable tenure as CEO with the
various successes and challenges faced by the business over the
years. We wish Dimitri every success in his future endeavours.
I am delighted to welcome Sanjeev to the Board. Sanjeev's
experience, in both operational scaling of drug development
businesses and his direct experience of engaging with investors
both in the UK and internationally, will provide us with the
appropriate skills and knowledge that we require for the next stage
of our journey with ImmuPharma and he will be an excellent
complement to Dr Tim Franklin, COO, who was recently appointed to
the Board.
I am also extremely pleased to welcome Lisa to the Board. Having
worked with Lisa over a number of years, I have been continually
impressed by her leadership skills and work ethic. Lisa has an
intimate knowledge of how ImmuPharma operates and is integral to
shareholder communication and representation and she will
contribute an enormous amount to the quality of the Board.
With my appointment as CEO, leading ImmuPharma through this next
significant period, I am determined, working with the excellent
team around me, in building shareholder value by progressing the
development and commercialisation of all the key assets in our
portfolio."
End
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED
UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014
WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL)
ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A
REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO
BE IN THE PUBLIC DOMAIN.
The following information is disclosed pursuant to Rule 17 and
Schedule Two paragraph (g) of the AIM Rules for Companies in
relation to Sanjeev Pandya (aged 48).
Current Directorships Past Directorships held within
last 5 years
Redcliffe Healthcare Limited
Odin Healthcare Ltd
Advanced Oncotherapy PLC
AVO (China) LTD
The London Proton Therapy Centre
Limited
Sanjeev Pandya holds no ordinary shares in the capital of the
Company.
The following information is disclosed pursuant to Rule 17 and
Schedule Two paragraph (g) of the AIM Rules for Companies in
relation to Lisa Baderoon (aged 54).
Current Directorships Past Directorships held within
last 5 years
Just B Communications Limited Ark Analytics Solutions Limited
Lisa Baderoon currently holds 43,963 ordinary shares and
1,100,000 options over ordinary shares in the Company.
For further information please contact:
ImmuPharma PLC ( www.immupharma.com )
Tim McCarthy, Chief Executive Officer + 44 (0) 207 152 4080
Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin +44 (0) 203 36 8 3550
Stanford Capital Partners (Joint Broker)
Patrick Claridge +44 (0) 203 815 8880
John Howes
Bob Pountney
SI Capital (Joint Broker)
Nick Emerson +44 (0) 1483 413500
4Reliance (Euronext Growth Listing Sponsor) +32 (0) 2 747 02 60
Jean-Charles Snoy
Degroof Petercam (Liquidity Provider) +32 (0) 2 287 95 34
Erik De Clippel
Backstage Communication
Olivier Duquaine +32 (0) 477 504 784
Gunther De Backer +32 (0) 475 903 909
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a
specialty biopharmaceutical company that discovers and develops
peptide-based therapeutics. The Company's portfolio includes novel
peptide therapeutics for autoimmune diseases, metabolic diseases,
anti-infectives and cancer. The lead program, Lupuzor(TM), is a
first-in class autophagy immunomodulator which is in Phase 3 for
the treatment of lupus and preclinical analysis suggest therapeutic
activity for many other autoimmune diseases that share the same
autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals
signed on 28 November 2019, an exclusive licence and development
agreement and trademark agreement for Lupuzor(TM) to fund a new
international Phase 3 trial for Lupuzor(TM) and commercialise in
the US.
For additional information about ImmuPharma please visit
www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity Identifier) code:
213800VZKGHXC7VUS895.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAKZGFNKGZGMZG
(END) Dow Jones Newswires
July 30, 2021 02:00 ET (06:00 GMT)
Immupharma (LSE:IMM)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Immupharma (LSE:IMM)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
